{"id":"losartan-hydrochlorothiazide-if-necessary","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Cough"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Losartan works by blocking the angiotensin II receptor, which is part of the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure. By blocking this receptor, losartan prevents the vasoconstriction and fluid retention caused by angiotensin II, leading to a decrease in blood pressure. Hydrochlorothiazide, on the other hand, increases urine production by inhibiting the sodium-chloride cotransporter in the distal convoluted tubule, which leads to a decrease in fluid volume and a subsequent decrease in blood pressure.","oneSentence":"Losartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to relax blood vessels and lower blood pressure. Hydrochlorothiazide is a thiazide diuretic that increases urine production to reduce blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:36.006Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT00546052","phase":"PHASE3","title":"A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09-01","conditions":"Hypertension, Metabolic Disorder","enrollment":1738},{"nctId":"NCT02900729","phase":"PHASE3","title":"Randomized Controlled Trial of Renal Denervation for Resistant Hypertension","status":"UNKNOWN","sponsor":"Shanghai WiseGain Medical Devices Co., Ltd.","startDate":"2016-10","conditions":"Hypertension","enrollment":254},{"nctId":"NCT00751751","phase":"PHASE3","title":"Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2003-06","conditions":"Essential Hypertension","enrollment":441}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"losartan + hydrochlorothiazide, if necessary","genericName":"losartan + hydrochlorothiazide, if necessary","companyName":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","companyId":"daiichi-sankyo-europe-gmbh-a-daiichi-sankyo-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Losartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to relax blood vessels and lower blood pressure. Hydrochlorothiazide is a thiazide diuretic that increases urine production to reduce blood pressure. Used for Hypertension, Chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}